Structured Assessment for Prospective Identification of Safety Signals in Electronic Medical Records: Evaluation in the Health Improvement Network

Drug Safety

Volumn 38, Issue 1, 2015, Pages 87-100

  Cederholm, S ^a   Hill, G ^a   Asiimwe, A ^b   Bate, A ^c   Bhayat, F ^d   Persson Brobert, G ^e   Bergvall, T ^a   Ansell, D ^f   Star, K ^a   Noren G N ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b Eli Lilly UK   (United Kingdom)

^c Pfizer UK   (United Kingdom)

^d TGRD (Europe)   (United Kingdom)

^e BAYER PHARMA AG   (Germany)

^f Cegedim Strategic Data Medical Research ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; DITHRANOL; DRUG; GENTAMICIN; PAROXETINE; SALMETEROL; SCOPOLAMINE; SCOPOLAMINE BUTYL BROMIDE;

ABDOMINAL CRAMP; ARTICLE; AUDITORY TUBE DYSFUNCTION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; COMPUTER INTERFACE; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; ENDOMETRIOSIS; EPIPHORA; HEALTH IMPROVEMENT NETWORK; HUMAN; MULTIPLE ORGAN FAILURE; NORMAL HUMAN; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROCESS MONITORING; RISK ASSESSMENT; SENSORY DYSFUNCTION; SIDE EFFECT; SIGNAL DETECTION; SKIN SENSATION DISTURBANCE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORD; PROSPECTIVE STUDY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORDS; HUMANS; PHARMACOVIGILANCE; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES;

EID: 84988268884     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0251-y     Document Type: Article

References (21)

1. Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Dis. 2010;20(3):361–87.
2. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Inter Med. 2010;153(9):600–6.
3. Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011;62:1–10 (Epub 2010/09/03).
4. Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20(1):1–11.
5. Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007;16(12):1275–84.
6. Jick H. The discovery of drug-induced illness. N Eng J Med. 1977;296:481–5.
7. Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13–23.
8. Ryan PB, Madigan D, Stang PE, MarcOverhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15 (Epub 2012/09/28).
9. Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A Comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(S1):143–58.
10. Harpaz R, Vilar S, DuMouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20(3):413–9.
11. Yih WK, Kulldorff M, Fireman BH, Shui IM, Lewis EM, Klein NP, et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink Project. Pediatrics. 2011;127(Supplement 1):S54–64.
12. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Primary Care. 2011;19(4):251–5 (Epub 2011/01/01).
13. Blak BT, Thompson M. How does The Health Improvement Network (THIN) data on prevalences on chronic diseases compare with national figures? Value Health. 2009;12(7):A253.
14. Lindquist M. Vigibase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42(5):409–19.
15. Trifiro G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salame G, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176–84 (Epub 2009/09/17).
16. Norén GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(1):107–21.
17. Norén GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: results on real-world data. Pharmacoepidemiol Drug Saf. 2012;21(6):673–5.
18. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:5.
19. Juhlin K, Ye X, Star K, Norén GN. Outlier removal to uncover patterns in adverse drug reaction surveillance—a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22(10):1119–29 (Epub 2013/07/09).
20. Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):32–40 (Epub 2012/01/25).
21. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 1997;17(6):374–89.